Home › Funds › Alger Health Sciences Fund
Fund family: ALGER FUNDS · Filed by ALGER FUNDS (CIK 3521) · SEC series S000009164
Share classes and tickers: AHSAX (C000024915), AHSCX (C000024917), AHSZX (C000156505)
“With management” counts the items where the fund’s own filing gives management’s recommendation (FOR or AGAINST): 618 with, 17 against, 0 abstentions (not counted as with management). Shareholder proposals: 13 FOR, 3 AGAINST, 0 abstained, by the filing’s own vote-source field.
Each ballot item this fund voted is set against the votes of the other ALGER FUNDS funds and accounts on the same item (same meeting, same proposal): “most funds” is a strict majority of at least three of them, FOR against AGAINST, WITHHOLD or ABSTAIN, with split votes and items not voted left out. Funds in one family can follow separate voting policies, for example ESG funds, sub-advised funds and funds using pass-through voting.
Voted the same way as most ALGER FUNDS funds on all 107 items where a comparison was possible.
The same votes as “with management” above, by the sector of the company voted on. 76.9% of this fund’s 635 such votes could be given a sector; the other 147 (23.1%) are at companies without one and are not in the table.
| Sector | Votes | Against management | Share |
|---|---|---|---|
| Health Care | 423 | 15 | 3.5% |
| Real Estate | 30 | 0 | 0.0% |
| Consumer Staples | 17 | 1 | 5.9% |
| Technology | 10 | 0 | 0.0% |
| Finance | 8 | 0 | 0.0% |
| Proposal type | Items | Against management |
|---|---|---|
| Director Elections | 405 | 0 |
| Audit-related | 58 | 0 |
| Say-on-Pay | 49 | 0 |
| Corporate Governance | 46 | 10 |
| Compensation | 37 | 0 |
| Capital Structure | 31 | 0 |
| Other Social Issues | 6 | 4 |
| Environment or Climate | 3 | 3 |
| Extraordinary Transactions | 1 | 0 |
| Other | 1 | 0 |
Position = shares voted × a recent share price, for US-listed shares of companies with a page on this site; an estimate for ranking only.
| Company | Meeting | Est. position | Items | Against mgmt |
|---|---|---|---|---|
| McKesson Corporation | July 30, 2025 | $5M | 14 | 0 |
| Cardinal Health, Inc. | November 5, 2025 | $4M | 14 | 0 |
| Teva Pharmaceutical Industries Limited | May 28, 2026 | $3M | 3 | 0 |
| Veeva Systems Inc. | June 17, 2026 | $3M | 10 | 0 |
| Welltower Inc. | May 21, 2026 | $3M | 11 | 0 |
| Merck & Co., Inc. | May 26, 2026 | $3M | 18 | 3 |
| Johnson & Johnson | April 23, 2026 | $3M | 15 | 1 |
| Eli Lilly and Company | May 4, 2026 | $3M | 10 | 2 |
| Meeting | Company | Proposal | Fund | Mgmt |
|---|---|---|---|---|
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on DEI risks in federal contracting. Shareholder proposal | Against | For |
| May 26, 2026 | Merck & Co., Inc. | Shareholder proposal regarding a report on healthcare coverage gaps. Shareholder proposal | Against | For |
| April 23, 2026 | Johnson & Johnson | Independent Board Chair Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to adopt a policy and amend the bylaws to require an independent board chair. Shareholder proposal | For | Against |
| May 4, 2026 | Eli Lilly and Company | Shareholder proposal to prepare an annual lobbying report. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting an independent Board Chair policy, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| April 30, 2026 | Gilead Sciences, Inc. | To vote on a stockholder proposal requesting a report on the impact of extended patent exclusivities on patient access, if properly presented at the Annual Meeting. Shareholder proposal | For | Against |
| May 8, 2026 | AbbVie Inc. | Stockholder Proposal - to Adopt a Policy to Require an Independent Chair Shareholder proposal | For | Against |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding a report on healthcare consequences. Shareholder proposal | For | Against |
| April 23, 2026 | HCA Healthcare, Inc. | Stockholder proposal, if properly presented at the meeting, regarding stockholders' right to act by written consent. Shareholder proposal | For | Against |
| May 14, 2026 | CVS Health Corporation | Stockholder Proposal for Reducing the Threshold for Our Stockholder Right to Act By Written Consent. Shareholder proposal | For | Against |
| May 12, 2026 | Centene Corporation | STOCKHOLDER PROPOSAL REGARDING AN INDEPENDENT BOARD CHAIRMAN. Shareholder proposal | For | Against |
638 ballot items at 54 meetings in 2025-2026. Download all votes (CSV)
Recent votes against management’s recommendation at large companies.
In the 2025-2026 proxy season, Alger Health Sciences Fund (AHSAX) voted at 54 shareholder meetings of 54 companies, on 638 ballot items in all. Where management made a recommendation, the fund followed it on 97.3% of the items and voted against it 17 times. Its most frequent area of disagreement was corporate governance (10 of its votes against management). It voted on 16 shareholder proposals. It voted the same way as most ALGER FUNDS funds on every item where a comparison was possible.
Every figure is derived from the fund’s own Form N-PX filings with the SEC, read item by item: one ballot item is the fund’s vote on one proposal at one meeting, and an item filed twice in the season is counted once. Percentages count items, never shares. A season is published only with at least 250 ballot items at 15 meetings. Built November 18, 2026. The interactive database shows the same votes company by company, with every other fund that voted.